{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:45:24Z","timestamp":1791942324901,"version":"4.3.4"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Variant acute promyelocytic leukemia (APL) showed quite different aspects, and the current treatments remained challenged at present. Venetoclax, a selective inhibitor of B-cell lymphoma 2 (BCL-2), is a small molecule that has been studied in several hematologic malignancies as both monotherapy and in combination with other agents. However, there is little of its use in the treatment of APL or variant APL. In this report, we identified THRAP3 as novel RARA fusion in resembling APL, which was resistant to all-trans retinoic acid (ATRA) combined arsenic trioxide (ATO) chemotherapy. Then, the patient was salvaged by low-dose venetoclax and decitabine. The treatment in this case demonstrates the potential ability of venetoclax in variant APL, thus providing a new treatment option for all kinds of APL.<\/jats:p>","DOI":"10.3389\/fonc.2022.828852","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T05:11:56Z","timestamp":1644210716000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Clinical Response to Venetoclax and Decitabine in Acute Promyelocytic Leukemia With a Novel RARA-THRAP3 Fusion: A Case Report"],"prefix":"10.3389","volume":"12","author":[{"given":"Baoquan","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0813280106","article-title":"Long-Term Efficacy and Safety of All-Trans Retinoic Acid\/Arsenic Trioxide-Based Therapy in Newly Diagnosed Acute Promyelocytic Leukemia","volume":"106","author":"Hu","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4006","article-title":"Use of All-Trans Retinoic Acid Plus Arsenic Trioxide as an Alternative to Chemotherapy in Untreated Acute Promyelocytic Leukemia","volume":"107","author":"Estey","year":"2006","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040967","article-title":"Classic and Variants APLs, as Viewed From a Therapy Response","volume":"12","author":"Geoffroy","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40364-021-00284-x","article-title":"Current Views on the Genetic Landscape and Management of Variant Acute Promyelocytic Leukemia","volume":"9","author":"Zhang","year":"2021","journal-title":"Biomark Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-0103-x","article-title":"Integrated Analysis of Patient Samples Identifies Biomarkers for Venetoclax Efficacy and Combination Strategies in Acute Myeloid Leukemia","volume":"1","author":"Zhang","year":"2020","journal-title":"Nat Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17642","article-title":"A Novel HNRNPC-RARA Fusion in Acute Promyelocytic Leukaemia Lacking PML-RARA Rearrangement, Sensitive to Venetoclax-Based Therapy","volume":"195","author":"Liu","year":"2021","journal-title":"Br J Haematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.693670","article-title":"Treatment of Central Nervous System Relapse in Acute Promyelocytic Leukemia by Venetoclax: A Case Report","volume":"11","author":"Zhang","year":"202","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/mc.23276","article-title":"Identification of a Novel TNRC18-RARA Fusion in Acute Promyelocytic Leukemia Lacking T(15;17) (Q24;Q12)\/PML-RARA","volume":"60","author":"Wang","year":"2021","journal-title":"Mol Carcinog"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0095-z","article-title":"Identification of a Novel CPSF6-RARG Fusion Transcript in Acute Myeloid Leukemia Resembling Acute Promyelocytic Leukemia","volume":"32","author":"Qin","year":"2018","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.244715","article-title":"Novel Reciprocal Fusion Genes Involving HNRNPC and RARG in Acute Promyelocytic Leukemia Lacking RARA Rearrangement","volume":"105","author":"Su","year":"2020","journal-title":"Haematologica"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-828269","article-title":"BCL-2 Inhibition in AML: An Unexpected Bonus","volume":"132","author":"Konopleva","year":"2018","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04530-y","article-title":"Venetoclax and Decitabine in Refractory TP53-Mutated Early T-Cell Precursor Acute Lymphoblastic Leukemia","author":"Kong","year":"2021","journal-title":"Ann Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.209478","article-title":"Serendipity: Decitabine Monotherapy Induced Complete Molecular Response in a 77-Year-Old Patient With Acute Promyelocytic Leukemia","volume":"104","author":"Abboud","year":"2019","journal-title":"Haematologica"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.828852\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T05:11:58Z","timestamp":1644210718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.828852\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,7]]},"references-count":13,"alternative-id":["10.3389\/fonc.2022.828852"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.828852","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,7]]},"article-number":"828852"}}